Latest / Stock Movers / Meta’s $95 Billion Stock Offering; Moderna Down; Tesla Shares Up
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios. Podcasts. Radio.
- 0:06Speaker 2: News.
- 0:08Speaker 1: The Stock Movers Report. Your roundup of companies making moves
- 0:12Speaker 1: in the stock market. Harnessing the power of Bloomberg data.
- 0:15Speaker 2: Let's see what some stock movers are happening out there.
- 0:19Speaker 2: We're going to do that with Tatiana.
- 0:20Speaker 1: Daria, strategist for MarketSlide. Tatiana, what are you looking at today?
- 0:24Speaker 2: I'm looking at MetaShares swinging here quite a bit in
- 0:27Speaker 2: today's trading session. It was down about 2%, and now
- 0:31Speaker 2: it's about flat or slightly higher. Investors are still wrapping
- 0:34Speaker 2: their heads around its latest $ 95 billion combined stock offerings,
- 0:39Speaker 2: one of the largest in history. The company is offering
- 0:42Speaker 2: about $ 35 billion of common and preferred stock, and it
- 0:45Speaker 2: also has plans to raise as much as $ 60 billion
- 0:49Speaker 2: in a separate at-the-market share program. And it also disclosed
- 0:53Speaker 2: that NVIDIA, AMD, and Broadcom had agreed to buy as
- 0:57Speaker 2: much as $ 5 billion of those common shares in aggregate,
- 1:00Speaker 2: so perhaps reviving some of those circular financing concerns there. Again,
- 1:06Speaker 2: I mean, this was kind of expected after they announced
- 1:09Speaker 2: that new class of non-voting stocks share alongside earnings last week.
- 1:15Speaker 2: Just the magnitude of these announcements is what's perhaps taking
- 1:19Speaker 2: investors by surprise here.
- 1:21Speaker 1: Absolutely.
- 1:21Speaker 2: All right, next up on your list. It is Moderna.
- 1:24Speaker 2: That stock is down by about, it was down about 8%.
- 1:29Speaker 2: Now it's slightly under 1%. The drugmaker gave results from
- 1:33Speaker 2: a trial of its experimental vaccine used in the treatment
- 1:37Speaker 2: of pancreatic And BI analysts here say that the data
- 1:41Speaker 2: failed to beat BioNTech's survival treatment or even chemotherapy, so
- 1:47Speaker 2: a little bit underwhelming. Note, though, this is separate from
- 1:50Speaker 2: the leaked data we got on melanoma last week, which
- 1:54Speaker 2: drove all of that sharp moves in the market. So
- 1:58Speaker 2: it looks like investors are still digesting those results. They
- 2:01Speaker 2: did give an update over the weekend for those. For now,
- 2:05Speaker 2: they call that data approvable. Though questions linger over how
- 2:09Speaker 2: much else can we go into the solid tumors based
- 2:13Speaker 2: on the breakthroughs made.
- 2:14Speaker 1: In melanoma alone. All right. One more.
- 2:16Speaker 2: And Tesla here, a big mover today, up 6%. This
- 2:20Speaker 2: is all driven by excitement about a potential takeover from
- 2:25Speaker 2: SpaceX that has prompted analysts to upgrade their rating on
- 2:31Speaker 2: the stock. Barclays is the latest one to lift it
- 2:34Speaker 2: to an overweight from equal weight and assigning a new
- 2:37Speaker 2: price target of $ 450. I have to say that that
- 2:41Speaker 2: average price target has been drifting higher and higher. It's
- 2:45Speaker 2: now pointing to $ 418 a share or about 7% higher.
- 2:50Speaker 2: Investors here are looking past the cash burn, past the
- 2:53Speaker 2: earnings concerns. And M & A is the single most
- 2:58Speaker 2: biggest thing they care about right now.
- 3:00Speaker 1: The Stock Movers Report from Bloomberg Radio. Check back with
- 3:04Speaker 1: us throughout the day for the latest roundup of companies
- 3:07Speaker 1: making news on Wall Street. And for the latest market-moving headlines,
- 3:11Speaker 1: listen to Bloomberg Radio Live. Catch us on YouTube, Bloomberg.com,
- 3:16Speaker 1: and on Apple CarPlay and Android Auto with the Bloomberg
- 3:19Speaker 1: Business app.